Thrombosis management

SEPTEMBER 30, 2019

[Effectiveness and safety of rivaroxaban in patients with cancer-associated venous thrombosis ]

KOHN CG, LYMAN GH, BEYER-WESTENDORF J, SPYROPOULOS AC, BUNZ TJ, BAKER WL, ERIKSSON D, MEINECKE AK, COLEMAN CI

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population ]

SCHIELE F, PUYMIRAT E, FERRIÈRES J, T Simon, FOX KAA, EIKELBOOM J, DANCHIN N FAST-MI investigators

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[Rivaroxaban with or without aspirin for the secondary prevention of cardiovascular disease: clinical implications of the COMPASS Trial ]

STEPHEN J. Nicholls, NELSON J. Adam

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure]

MARTINEZ BK, BUNZ TJ, ERIKSSON D, MEINECKE AK, SOOD NA, COLEMAN CI

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[Influence of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation ]

MARTINEZ BK, BAKER WL, SOOD NA, BUNZ TJ, MEINECKE AK, ERIKSSON D, COLEMAN CI

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[Rivaroxaban administration after acute ischemic stroke: The RELAXED study ]

YASAKA M, MINEMATSU K, TOYODA K, MORI E, HIRANO T, HAMASAKI T, YAMAGAMI H, NAGAO T, YOSHIMURA S, UCHIYAMA S

[ ]

HUN

Thrombosis management

SEPTEMBER 30, 2019

[Influence of renal function on the pharmacokinetics, vitamin K antagonist oral anticoagulants ]

MATTHEW R. Weir, REINHOLD Kreutz

[ ]

HUN